Skip to main content

Table 1 Suggested dose and number of fractions per tumor site

From: Phase I/II trial of Durvalumab plus Tremelimumab and stereotactic body radiotherapy for metastatic head and neck carcinoma

Site Dose (Gy) Fractions
Lung-peripheral 45 3
Lung-central 50 5
Mediastinal/cervical lymph node 50 5
Liver 45 3
Spinal/paraspinal 30 3
Osseous 30 3
Abdominal-pelvic metastasis (lymph node/adrenal gland) 45 3